Sélectionner la langue
NPR1
NPR1 Informations sur la molécule
| Nom anglais | Natriuretic peptide receptor 1 | Nombre de médicaments commercialisés | 4 |
| Nombre de médicaments cliniques | 7 | Alias de la cible | EC:4.6.1.2，Atrionatriuretic Peptide Receptor A，Natriuretic Peptide Receptor A，ANPRA，Atrial Natriuretic Peptide Receptor 1，Natriuretic Peptide A Type Receptor，Testicular Tissue Protein Li 20，EC 4.6.1.2，GUCY2A，GUC2A，ANPa，NPRA，GC-A，NPR-A，NPR1，Guanylate cyclase A，ANP-A，Natriuretic Peptide Receptor 1，Atrial Natriuretic Peptide Receptor Type A，ANPR-A，Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A) |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Natriuretic peptide receptor 1 |
| Alias de la cible | EC:4.6.1.2，Atrionatriuretic Peptide Receptor A，Natriuretic Peptide Receptor A，ANPRA，Atrial Natriuretic Peptide Receptor 1，Natriuretic Peptide A Type Receptor，Testicular Tissue Protein Li 20，EC 4.6.1.2，GUCY2A，GUC2A，ANPa，NPRA，GC-A，NPR-A，NPR1，Guanylate cyclase A，ANP-A，Natriuretic Peptide Receptor 1，Atrial Natriuretic Peptide Receptor Type A，ANPR-A，Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A) |
| Nombre de médicaments commercialisés | 4 |
| Nombre de médicaments cliniques | 7 |
| Phase de R&D la plus avancée | Approved |
NPR1 Liste de produits
- Attribut
Protein (5)Cell (2)
- Bibliothèque de produits
En ligne (7)
- Espèces
Human (5)Mouse (1)Cynomolgus (1)
- Étiquette
Fc Tag (1)His Tag & Avi Tag (1)His Tag (3)- (2)
- Marqueur
Unconjugated (4)Biotin-labeled (1)- (2)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT NP1-H5259 |  Human | HEK293 | Human NPR1 / NPRA Protein, Fc Tag (MALS verified) |  |  |  |  Ajouter au panier |
HOT NP1-H82E9 | Human | HEK293 | Biotinylated Human NPR1 / NPRA Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier |
HOT NP1-M52H3 |  Mouse | HEK293 | Mouse NPR1 / NPRA Protein, His Tag, low endotoxin (MALS verified) | | | Ajouter au panier | |
CCHO-ATP290 | Human | CHO | CHO/Human NPR1 Stable Cell Line |  | Ajouter au panier | ||
CHEK-ATP245 | Human | HEK293 | HEK293/Human NPR1 Stable Cell Line | | Ajouter au panier | ||
NP1-H52H3 | Human | HEK293 | Human NPR1 / NPRA Protein, His Tag (MALS verified) | | | Ajouter au panier | |
NP1-C52H3 |  Cynomolgus | HEK293 | Cynomolgus NPR1 / NPRA Protein, His Tag (MALS verified) | | Ajouter au panier |
Quantité totale7
- 1
NPR1Contexte de la molécule
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate cyclase activity upon binding of the ligand.
NPR1Alias de la molécule
Atrial natriuretic peptide receptor 1,NPR1,NPRA,GC-A,ANPRA,NPR-A
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Recombinant human brain natriuretic peptide(Shijiazhuang wotai) | Phase 3 Clinical | Shijiazhuang wotai Biotechnology Co Ltd | Acutely decompensated congestive heart failure; Heart Failure | Details | |
| Recombinant human brain natriuretic peptide (Shanghai Jiao Tong University) | Phase 3 Clinical | Shanghai Jiaotong University | Heart Defects, Congenital; Tetralogy of Fallot | Details | |
| Nesiritide | BNP-32 (human); JNS-004; hBNP; SC-70400 | Phase 2 Clinical | Johnson & Johnson | Acutely decompensated congestive heart failure; Cardiomyopathies; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Dyspnea; Heart Failure; Heart Failure, Systolic; Hyperemia; Hyperinsulinism; Hypertension; Myocardial Ischemia; Obesity; Renal Insufficiency; Sleep Disorders, Circadian Rhythm | Details |
| Baloncibart | REGN-7544; REGN7544 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Hypotension; Postural Orthostatic Tachycardia Syndrome | Details |
| XXB-750 | XXB-750 | Phase 2 Clinical | Novartis Pharma Ag | Heart Failure; Heart Failure, Systolic; Hypertension | Details |
| GNP | Phase 2 Clinical | Guangzhou Leien Kangya Biomedical Technology Co Ltd | Acutely decompensated congestive heart failure; Heart Failure | Details | |
| REGN-5381 | REGN-5381 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Heart Failure; Hypertension | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human brain natriuretic peptide (Tibet Rhodiola) | Approved | Tibet Rhodiola Pharmaceutical Holding Company | 新活素 | Mainland China | Heart Failure | Chengdu Rhodiola Bio-Pharmaceutical Co Ltd | 2005-04-11 | Acutely decompensated congestive heart failure; Heart Failure | Details | |
| Sodium Nitroprusside | SNP | Approved | F. Hoffmann-La Roche Ltd | Nipride, Nitriate, Nitropress | Mainland China | Heart Failure; Hypertension | China Resources Double-Crane Pharmaceutical Co Ltd | 1974-05-10 | Healthy Aging; Heart Failure; Hypertension; Hypotension; Myocardial Infarction; Pulmonary Edema; Schizophrenia | Details |
| Recombinant human brain natriuretic peptide (Suzhou Landing Bioteh) | Approved | Suzhou RxD Biopharmaceutical Co Ltd | Mainland China | Heart Failure | Suzhou RxD Biopharmaceutical Co Ltd | 2025-04-30 | Heart Failure | Details | ||
| Carperitide | SUN-Y4936r; alpha-hANP; ANF (99-126); SUN-4936r; ANP (99-126); CDD (99-126); SUN-4936; SUN-4936h | Approved | Daiichi Sankyo Co Ltd | HANP | Japan | Heart Failure | Daiichi Sankyo Co Ltd | 1995-01-20 | Cardiomyopathies; Heart Failure; Respiratory Distress Syndrome, Adult | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques
Partager vers :